ArticlePloS one2016

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.

Shuyan Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.